Global Societal Burden of Alzheimer's Disease by Severity: a Targeted Literature Review [0.03%]
阿尔茨海默病不同患病程度所致全球社会负担的目标文献回顾
Maria A Cavaco,Se Ryeong Jang,Christopher Olsen et al.
Maria A Cavaco et al.
Introduction: Alzheimer's disease (AD) is among the costliest of illnesses for the elderly, placing a significant burden on healthcare systems and caregivers. Despite the depth of evidence, reviews lack a holistic assessm...
Emily Hoffmann,Hermann Krähling,Moritz Kleinevoss et al.
Emily Hoffmann et al.
Introduction: Perimesencephalic subarachnoid hemorrhage (pmSAH) is a rare, typically benign subtype of non-aneurysmal subarachnoid hemorrhage (SAH). While the majority of patients demonstrate a positive recovery trajector...
Differences in Patient-Physician Satisfaction for Migraine Treatment Medications in Patients with and without Medication-Overuse Headache: A Cross-Sectional Real-World Survey [0.03%]
有和没有药物过量性头痛的偏头痛患者对治疗药物的医患满意度差异：横断面真实世界调查
Ryotaro Ishii,Takahiro Kitano,Masahiro Iijima et al.
Ryotaro Ishii et al.
Introduction: Medication overuse headache (MOH) is incurred by the excessive use of acute medications, including over-the-counter (OTC) treatments. This study aimed to characterize the burden, management, and treatment sa...
Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray [0.03%]
有关难治性抑郁症患者使用艾斯氯胺酮鼻用喷雾剂的医保受惠者档案研究
Kristin Clemens,Maryia Zhdanava,Amanda Teeple et al.
Kristin Clemens et al.
Introduction: While the literature on esketamine use in commercially insured patients with treatment-resistant depression (TRD) is growing, data on Medicaid beneficiaries remain limited. This study aimed to fill this gap ...
Treatment Adherence in MS: Does Objective MS Knowledge and MS Risk Knowledge Matter in Relation to Perceived Disease-Modifying Therapy Benefits? [0.03%]
多发性硬化症患者的治疗依从性：客观的疾病知识和风险认知对于患者感知到的疾病修正疗法效果有何影响？
Edward Smith,Dawn Langdon
Edward Smith
Introduction: The effectiveness of disease-modifying therapies (DMTs) in managing MS has been established, although adherence is commonly difficult to achieve, which can undermine health outcomes. People with MS (pwMS) wh...
Benjamin W Y Lo,Hitoshi Fukuda
Benjamin W Y Lo
This review summarizes current concepts in our understanding of stroke anatomy, pathophysiology of cerebral hypoperfusion, and collateral circulation. It also provides an evidence-based update in stroke trials and treatments assessed using ...
Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis Treatment [0.03%]
疗效之外：首次治疗多发性硬化症的持久性、无疾病证据状态和治疗决策能力
Clara Helena López-Caneda,Sergio Antón-Fuente,Maria José Pérez-Haro et al.
Clara Helena López-Caneda et al.
Introduction: Injectable drugs, including interferon-beta and glatiramer acetate (collectively referred to as BRACE), dimethyl fumarate (DMF), and teriflunomide (TER) are commonly used as initial disease-modifying therapi...
Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study [0.03%]
利司普兰在日本脊髓性肌萎缩症患者中的安全性：一项上市后监测研究的12个月中期分析结果
Kayoko Saito,Toshio Saito,Reiko Arakawa et al.
Kayoko Saito et al.
Introduction: Risdiplam, an oral splicing modifier for the survival motor neuron-2 gene (SMN2), is approved for treating spinal muscular atrophy (SMA). While its safety and efficacy have been demonstrated in global trials...
Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management [0.03%]
重症肌无力的皮质类固醇使用：日常管理专家意见
Renato Mantegazza,Giovanni Antonini,Matteo Gastaldi et al.
Renato Mantegazza et al.
Introduction: Myasthenia gravis, a rare autoimmune disorder characterized by muscle weakness and fatigue, it is a mainly B-cell mediated condition with antibodies directed against the acetylcholine receptor or functionall...
Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-country Discrete Choice Experiment [0.03%]
多国决策试验分析偏头痛患者对自注射预防性治疗的偏好
Jaein Seo,Caitlin Thomas,Tommi Tervonen et al.
Jaein Seo et al.
Introduction: Self-injectable calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) and oral CGRP antagonists are currently available for migraine prevention. This study elicited the preferences of participant...